Total Payments
$1,819
2024 Payments
$927.93
Companies
20
Transactions
108
Medicare Patients
1,667
Medicare Billing
$105,844
Payment Breakdown by Category
Food & Beverage$1,819 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,819 | 108 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $514.72 | 38 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $288.15 | 11 | $0 (2024) |
| Amgen Inc. | $269.44 | 16 | $0 (2024) |
| Lilly USA, LLC | $177.67 | 11 | $0 (2024) |
| Novo Nordisk Inc | $113.20 | 7 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $73.33 | 2 | $0 (2024) |
| GlaxoSmithKline, LLC. | $61.00 | 4 | $0 (2024) |
| Sumitomo Pharma America, Inc. | $59.99 | 4 | $0 (2024) |
| Mylan Specialty L.P. | $29.42 | 2 | $0 (2024) |
| PFIZER INC. | $28.87 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $927.93 | 51 | ABBVIE INC. ($220.52) |
| 2023 | $724.01 | 48 | ABBVIE INC. ($280.75) |
| 2022 | $167.53 | 9 | Bayer HealthCare Pharmaceuticals Inc. ($56.96) |
All Payment Transactions
108 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.82 | General |
| Category: Diabetes | ||||||
| 12/11/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $12.22 | General |
| Category: Inflammation | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.18 | General |
| 11/05/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: VACCINES | ||||||
| 11/01/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $11.95 | General |
| Category: Inflammation | ||||||
| 10/24/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: NEUROSCIENCE | ||||||
| 10/14/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.82 | General |
| Category: NEUROSCIENCE | ||||||
| 10/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: Cardio-renal | ||||||
| 10/10/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $13.27 | General |
| Category: VACCINES | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $27.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/04/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: Diabetes | ||||||
| 10/01/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: Bone Health | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/16/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: Inflammation | ||||||
| 09/12/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: NEUROSCIENCE | ||||||
| 09/10/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: NEUROSCIENCE | ||||||
| 09/06/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: Inflammation | ||||||
| 08/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: NEUROSCIENCE | ||||||
| 08/16/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $28.55 | General |
| Category: NEUROSCIENCE | ||||||
| 08/13/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: Diabetes | ||||||
| 08/05/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: Diabetes | ||||||
| 08/02/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $9.94 | General |
| Category: Inflammation | ||||||
| 07/30/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: Obesity | ||||||
| 07/28/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: NEUROSCIENCE | ||||||
| 06/28/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 523 | 1,500 | $121,944 | $33,361 |
| 2022 | 10 | 621 | 1,577 | $140,569 | $41,706 |
| 2021 | 11 | 523 | 1,063 | $86,021 | $30,777 |
Total Patients
1,667
Total Services
4,140
Medicare Billing
$105,844
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 159 | 287 | $71,176 | $19,157 | 26.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 80 | 92 | $15,640 | $3,896 | 24.9% |
| 87637 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | Office | 2023 | 23 | 27 | $10,665 | $3,774 | 35.4% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 35 | 35 | $4,725 | $2,648 | 56.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 18 | 18 | $4,104 | $1,838 | 44.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 35 | 35 | $1,400 | $1,002 | 71.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 71 | 122 | $5,612 | $904.29 | 16.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 60 | 738 | $3,690 | $57.95 | 1.6% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 25 | 128 | $4,608 | $45.02 | 1.0% |
| 81003 | Automated urinalysis test | Office | 2023 | 17 | 18 | $324.00 | $39.60 | 12.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 146 | 296 | $73,408 | $22,332 | 30.4% |
| 87637 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | Office | 2022 | 41 | 47 | $18,979 | $6,624 | 34.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 107 | 148 | $25,160 | $6,176 | 24.5% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 42 | 42 | $5,670 | $2,951 | 52.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 46 | 46 | $1,839 | $1,255 | 68.2% |
| 0124A | Fee covid-19 vac 13 res | Office | 2022 | 31 | 31 | $1,519 | $1,121 | 73.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 86 | 134 | $6,164 | $1,042 | 16.9% |
| 81003 | Automated urinalysis test | Office | 2022 | 36 | 53 | $954.00 | $117.68 | 12.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 64 | 684 | $3,420 | $53.18 | 1.6% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 22 | 96 | $3,456 | $34.76 | 1.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 160 | 344 | $58,480 | $19,470 | 33.3% |
| 0004A | Fee covid-19 vac 1 res | Office | 2021 | 98 | 98 | $4,410 | $3,647 | 82.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 30 | 36 | $8,928 | $2,799 | 31.4% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 30 | 30 | $3,300 | $1,993 | 60.4% |
| 0003A | Fee covid-19 vac 1 booster | Office | 2021 | 40 | 40 | $1,800 | $1,488 | 82.7% |
About Tonya Krieg, NP
Tonya Krieg, NP is a Nurse Practitioner healthcare provider based in Princeton, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2021. The National Provider Identifier (NPI) number assigned to this provider is 1598350910.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Tonya Krieg, NP has received a total of $1,819 in payments from pharmaceutical and medical device companies, with $927.93 received in 2024. These payments were reported across 108 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($1,819).
As a Medicare-enrolled provider, Krieg has provided services to 1,667 Medicare beneficiaries, totaling 4,140 services with total Medicare billing of $105,844. Data is available for 3 years (2021–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Nurse Practitioner
- Other Specialties Nurse Practitioner
- Location Princeton, IN
- Active Since 03/08/2021
- Last Updated 03/29/2021
- Taxonomy Code 363L00000X
- Entity Type Individual
- NPI Number 1598350910
Products in Payments
- VRAYLAR (Drug) $283.30
- UBRELVY (Drug) $156.65
- Otezla (Drug) $149.79
- FARXIGA (Drug) $138.42
- BREZTRI (Drug) $122.35
- MOUNJARO (Drug) $78.02
- QULIPTA (Drug) $74.77
- Kerendia (Drug) $73.33
- Repatha (Biological) $64.84
- GEMTESA (Drug) $59.99
- EVENITY (Biological) $54.81
- Rybelsus (Drug) $53.75
- TRULICITY (Drug) $49.24
- REXULTI (Drug) $39.64
- JARDIANCE (Drug) $35.31
- TRELEGY ELLIPTA (Drug) $32.13
- Wegovy (Drug) $30.68
- YUPELRI (Drug) $29.42
- SHINGRIX (Biological) $28.87
- Ozempic (Drug) $28.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nurse Practitioner Doctors in Princeton
Melissa Bogle, Fnp-Bc, FNP-BC
Nurse Practitioner — Payments: $4,650
Nurse Practitioner $4,650
Vonetta Vories, Fnp-C, FNP-C
Nurse Practitioner — Payments: $1,674
Nurse Practitioner $1,674
Kevin Liebmann
Nurse Practitioner — Payments: $1,663
Nurse Practitioner $1,663
Stephanie Mundy, Aprn, APRN
Nurse Practitioner — Payments: $1,477
Nurse Practitioner $1,477
Christine Deluca, Np, NP
Nurse Practitioner — Payments: $1,257
Nurse Practitioner $1,257
Mellisa Hall, N.p, N.P
Nurse Practitioner — Payments: $1,040
Nurse Practitioner $1,040